On behalf of Hanmi Pharmaceuticals, I express
our respect to World Korean Medical Organization (WMKO), who has played pivotal
roles for Korean Healthcare Professionals worldwide who have endeavored for
global health and happiness, and sincerely congratulate the first publication
of the World Korean Medical Journal (WKMJ) which would greatly contribute in
sharing and expanding WMKO’s activities. Also, we praise Chul-Soo Hyun, the
President of WKMO, and his leadership team for making such progress.
Hanmi, as one of the leading Korean
pharmaceuticals, has always strived to be a global company through R&D. As
a result, we have developed innovative novel drugs in Oncology and Biologics,
over ten of which are currently under multinational clinical trials in the US
and Europe.
In addition to innovative novel drugs, Hanmi
has developed a great number of Incrementally Modified Drugs (IMD) and
Fixed-Dose Combination (FDC) drugs, entering global markets by collaboration
with multinational companies such as Merck, Sanofi and GSK. Hanmi’s
“ESOMEPRAZOLE STRONTIUM Delayed Release Capsule 49.3 mg”, a pharmaceutical
alternative to NEXIUM® capsule 40 mg for a more affordable treatment option for
gastroesophageal reflux disease (GERD) in adult patients, was launched in the
US market in December 2013. Esomeprazole strontium is currently marketed in the
US by Hanmi’s US partner, Amneal Pharmaceuticals.
All such Hanmi’s R&D activities and global
market expansions have been supported by Korean Healthcare Professionals
worldwide. With the first publication of WKMJ as a momentum, we wish all
members of WKMO collaborate closely each other and support Korean
pharmaceuticals in entering global markets. Hanmi promises to do our best
efforts to contribute to the activities of WKMO in the future.
May the Year of the Blue Horse bring all WKMO
members health, happiness, and prosperity.
Thank you.
Gwan Sun Lee, PhD
President & CEO
Hanmi Pharm. Co., Ltd.